X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Aurobindo Pharma with Aventis Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AUROBINDO PHARMA vs SANOFI INDIA - Comparison Results

AUROBINDO PHARMA    Change

Aurobindo Pharma is one of India's top 5 pharma companies in terms of turnover, and has presence in the generic and Active Pharmaceutical Ingredients (API) segments. The company's robust product portfolio is spread across 6 product areas, including a... More

SANOFI INDIA 
   Change

Sanofi India (the erstwhile Aventis Pharma), the 60% subsidiary of Sanofi-Aventis SA, France, is one of the largest pharma MNCs in India with a turnover of over Rs 13.2 bn in CY11. Domestic sales constituted 81% of total sales in CY11 and exports con... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    AUROBINDO PHARMA SANOFI INDIA AUROBINDO PHARMA/
SANOFI INDIA
 
P/E (TTM) x 18.9 39.9 47.4% View Chart
P/BV x 4.8 8.6 55.2% View Chart
Dividend Yield % 0.3 1.0 31.3%  

Financials

 AUROBINDO PHARMA   SANOFI INDIA
EQUITY SHARE DATA
    AUROBINDO PHARMA
Mar-17
SANOFI INDIA
Dec-16
AUROBINDO PHARMA/
SANOFI INDIA
5-Yr Chart
Click to enlarge
High Rs8954,560 19.6%   
Low Rs6224,400 14.1%   
Sales per share (Unadj.) Rs254.61,028.5 24.8%  
Earnings per share (Unadj.) Rs39.3129.0 30.5%  
Cash flow per share (Unadj.) Rs46.6186.0 25.0%  
Dividends per share (Unadj.) Rs2.5068.00 3.7%  
Dividend yield (eoy) %0.31.5 21.7%  
Book value per share (Unadj.) Rs160.0753.6 21.2%  
Shares outstanding (eoy) m585.8823.03 2,544.0%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x3.04.4 68.4%   
Avg P/E ratio x19.334.7 55.6%  
P/CF ratio (eoy) x16.324.1 67.6%  
Price / Book Value ratio x4.75.9 79.8%  
Dividend payout %6.452.7 12.1%   
Avg Mkt Cap Rs m444,390103,174 430.7%   
No. of employees `00014.03.6 385.9%   
Total wages/salary Rs m17,6783,592 492.1%   
Avg. sales/employee Rs Th10,667.86,537.7 163.2%   
Avg. wages/employee Rs Th1,264.3991.4 127.5%   
Avg. net profit/employee Rs Th1,645.8819.8 200.8%   
INCOME DATA
Net Sales Rs m149,15723,686 629.7%  
Other income Rs m1,159708 163.7%   
Total revenues Rs m150,31624,394 616.2%   
Gross profit Rs m34,3435,281 650.3%  
Depreciation Rs m4,2761,313 325.7%   
Interest Rs m66715 4,448.0%   
Profit before tax Rs m30,5584,661 655.6%   
Minority Interest Rs m500-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m7,5971,691 449.2%   
Profit after tax Rs m23,0122,970 774.8%  
Gross profit margin %23.022.3 103.3%  
Effective tax rate %24.936.3 68.5%   
Net profit margin %15.412.5 123.0%  
BALANCE SHEET DATA
Current assets Rs m92,06215,673 587.4%   
Current liabilities Rs m66,2236,678 991.7%   
Net working cap to sales %17.338.0 45.6%  
Current ratio x1.42.3 59.2%  
Inventory Days Days10676 139.5%  
Debtors Days Days6822 303.3%  
Net fixed assets Rs m62,9198,098 777.0%   
Share capital Rs m586230 254.4%   
"Free" reserves Rs m93,13317,088 545.0%   
Net worth Rs m93,71917,356 540.0%   
Long term debt Rs m1,8140-   
Total assets Rs m162,49425,400 639.7%  
Interest coverage x46.8311.7 15.0%   
Debt to equity ratio x00-  
Sales to assets ratio x0.90.9 98.4%   
Return on assets %14.611.8 124.0%  
Return on equity %24.617.1 143.5%  
Return on capital %32.726.9 121.5%  
Exports to sales %024.5 0.0%   
Imports to sales %028.0 0.0%   
Exports (fob) Rs mNA5,801 0.0%   
Imports (cif) Rs mNA6,627 0.0%   
Fx inflow Rs m75,8387,145 1,061.4%   
Fx outflow Rs m30,2246,846 441.5%   
Net fx Rs m45,613299 15,255.3%   
CASH FLOW
From Operations Rs m32,7863,226 1,016.3%  
From Investments Rs m-17,870-1,555 1,149.2%  
From Financial Activity Rs m-19,153-1,818 1,053.5%  
Net Cashflow Rs m-4,239-147 2,883.5%  

Share Holding

Indian Promoters % 54.1 0.0 -  
Foreign collaborators % 0.0 60.4 -  
Indian inst/Mut Fund % 8.0 14.4 55.2%  
FIIs % 27.7 14.6 189.7%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.2 10.5 97.1%  
Shareholders   69,601 15,184 458.4%  
Pledged promoter(s) holding % 8.6 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare AUROBINDO PHARMA With:   GLENMARK PHARMA  FULFORD INDIA  DR. REDDYS LAB  PIRAMAL ENTERPRISES  JUBILANT LIFE SCIENCES  

Compare AUROBINDO PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Stock Market's Sudden Crash; Rising Oil Prices; Banking Stocks and Top Cues in Action Today(Pre-Open)

The Indian share markets ended lower on Friday. The S&P BSE Sensex partially recovered after crashing 1,000 points in intraday trade to settle 280 points lower.

Related Views on News

AUROBINDO PHARMA Announces Quarterly Results (1QFY19); Net Profit Down 12.0% (Quarterly Result Update)

Aug 13, 2018 | Updated on Aug 13, 2018

For the quarter ended June 2018, AUROBINDO PHARMA has posted a net profit of Rs 5 bn (down 12.0% YoY). Sales on the other hand came in at Rs 43 bn (up 15.5% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

SANOFI INDIA Announces Quarterly Results (1QFY19); Net Profit Up 35.1% (Quarterly Result Update)

Jul 27, 2018 | Updated on Jul 27, 2018

For the quarter ended June 2018, SANOFI INDIA has posted a net profit of Rs 996 m (up 35.1% YoY). Sales on the other hand came in at Rs 7 bn (up 13.8% YoY). Read on for a complete analysis of SANOFI INDIA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

My First Pharma Stock Recommendation!(The 5 Minute Wrapup)

Sep 21, 2018

This company has not only created a niche in the pharma space, it has done so profitably.

Want Bigger Returns Than You Thought Possible? This is Where You Should Look(Profit Hunter)

Sep 12, 2018

Richa has discovered the single most profitable opportunity in the market - read on to discover more...

Are You Blindly Investing In Equities? Read This...(Outside View)

Sep 11, 2018

PersonalFN explains how blindly investing in equities can prove hazardous to your wealth and health.

Investors Are Redeeming From Equity Mutual Funds Now. Should You?(Outside View)

Sep 12, 2018

PersonalFN elucidates if you should redeem from equity mutual fund now, and the approach to follow before you decide to sell mutual funds.

Outperformance of Strong Established Brands in the Indian Stock market(Chart Of The Day)

Sep 14, 2018

Strong Well established Indian Brands have comfortably outperformed the index in the decade post the global financial crisis.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

AUROBINDO PHARMA SHARE PRICE


Sep 21, 2018 (Close)

TRACK AUROBINDO PHARMA

  • Track your investment in AUROBINDO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON AUROBINDO PHARMA

AUROBINDO PHARMA - ALKEM LABORATORIES COMPARISON

COMPARE AUROBINDO PHARMA WITH

MARKET STATS